Spero Therapeutics, Inc. (SPRO) Key Metrics
SPRO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $64.1M
- Enterprise value
- $24.9M
- P/E (TTM)
- 7.9
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.4 10-yr median 13.6
- Price / book
- 1.7 10-yr median 1.8
- EV / EBITDA
- 3.8
- Dividend yield
- —
- Beta
- 1.50
SPRO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSPRO valuation Price multiples at each fiscal year-end price.
SPRO returns How much profit the business earns on the capital it uses.
SPRO per-share figures Results divided by the shares outstanding at year-end.
SPRO financial health Debt, liquidity and how easily interest is covered.
SPRO efficiency & capital use Working capital cycle and where the cash goes.
SPRO valuation history
SPRO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SPRO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SPRO cash returned to shareholders
SPRO price vs earnings per share
SPRO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $137.6M | $55.7M | $77.9M | $65.0M | $494.6M | $434.1M | $174.6M | $98.4M | — | — |
| Enterprise value | $100.2M | $7.1M | $7.1M | −$37.4M | $355.6M | $315.0M | $98.1M | −$16.8M | — | — |
| P/E ratio | 16.0 | — | 3.4 | — | — | — | — | — | — | — |
| Price / sales | 2.3 | 1.2 | 0.8 | 1.3 | 161.1 | 46.5 | 36.8 | 24.8 | — | — |
| Price / book | 2.3 | 1.2 | 0.7 | 0.9 | 5.6 | 3.3 | 2.3 | 0.8 | — | — |
| EV / sales | 1.7 | 0.1 | 0.1 | -0.8 | 115.8 | 33.8 | 20.7 | -4.2 | — | — |
| EV / EBITDA | 11.3 | — | 0.3 | — | — | — | — | — | — | — |
| Earnings yield | 6.2% | −123.2% | 29.3% | −71.4% | −18.1% | −17.9% | −34.5% | −42.3% | — | — |
| Free cash flow yield | −9.2% | −42.1% | −42.4% | −11.9% | −13.0% | −19.8% | −28.8% | −42.7% | — | — |
| Dividend yield | — | — | — | 83.8% | 9.6% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 83.8% | 9.6% | 0.0% | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $2.33 | $1.03 | $1.47 | $1.73 | $16.01 | $19.39 | $9.62 | $6.15 | $11.75 | — |
| Per share | ||||||||||
| Revenue per share | $1.01 | $0.89 | $1.96 | $1.29 | $0.10 | $0.42 | $0.26 | $0.25 | — | — |
| Earnings per share | $0.15 | −$1.27 | $0.43 | −$1.23 | −$2.91 | −$3.46 | −$3.31 | −$2.60 | — | — |
| Operating cash flow per share | −$0.21 | −$0.43 | −$0.62 | −$0.21 | −$2.08 | −$3.84 | −$2.75 | −$2.48 | — | — |
| Free cash flow per share | −$0.21 | −$0.43 | −$0.62 | −$0.21 | −$2.08 | −$3.84 | −$2.77 | −$2.63 | — | — |
| Cash per share | $0.68 | $0.98 | $1.44 | $2.90 | $4.74 | $5.67 | $4.52 | $7.21 | — | — |
| Book value per share | $1.00 | $0.85 | $2.02 | $2.02 | $2.86 | $5.90 | $4.11 | $7.24 | — | — |
| Tangible book value per share | $1.00 | $0.85 | $2.02 | $2.02 | $2.86 | $5.90 | $4.11 | $7.24 | — | — |
| Dividends per share | — | — | — | $1.45 | $1.54 | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $2.08 | $0.01 | $0.02 | $0.15 | — | — |
| Debt per share | $0.05 | $0.08 | $0.10 | $0.18 | $0.24 | $0.35 | $0.31 | $0.01 | — | — |
| Shares outstanding | 59.0M | 54.0M | 53.0M | 37.6M | 30.9M | 22.4M | 18.2M | 16.0M | — | — |
| Change in shares outstanding | +9.3% | +2.0% | +41.0% | +21.7% | +38.0% | +23.3% | +13.5% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 16.3% | −89.6% | 24.9% | −56.5% | −81.5% | −75.0% | −63.2% | −41.5% | −96.9% | −491.9% |
| Return on invested capital (ROIC) | −0.2% | — | 402.7% | — | — | — | — | — | — | — |
| Return on assets (ROA) | 9.6% | −46.8% | 14.8% | −31.4% | −55.3% | −59.7% | −51.2% | −37.5% | −86.0% | −243.4% |
| Return on tangible assets | 12.4% | −62.0% | 12.5% | −37.2% | −52.5% | −50.5% | −56.7% | −32.3% | −49.3% | −185.1% |
| Free cash flow margin | −21.2% | −48.9% | −31.8% | −15.9% | — | −922.1% | — | — | — | — |
| Income quality (OCF / net income) | −1.47 | — | −1.45 | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2.9M | $4.3M | $5.5M | $6.6M | $7.3M | $7.8M | $5.5M | $223,000 | $223,000 | — |
| Cash & short-term investments | $40.3M | $52.9M | $76.3M | $109.1M | $146.4M | $126.9M | $82.0M | $115.4M | $87.3M | $10.3M |
| Net debt | −$37.4M | −$48.6M | −$70.8M | −$102.5M | −$139.1M | −$119.1M | −$76.5M | −$115.2M | −$87.1M | −$10.3M |
| Debt / equity | 0.05 | 0.09 | 0.05 | 0.09 | 0.08 | 0.06 | 0.07 | 0.00 | 0.00 | — |
| Debt / assets | 0.04 | 0.04 | 0.03 | 0.05 | 0.04 | 0.05 | 0.05 | 0.00 | 0.00 | — |
| Net debt / EBITDA | −4.23 | — | −2.61 | — | — | — | — | — | — | — |
| Current ratio | 7.59 | 2.19 | 3.53 | 5.04 | 8.46 | 9.70 | 3.58 | 9.37 | 10.70 | 1.72 |
| Quick ratio | 7.59 | 2.19 | 3.53 | 5.25 | 8.48 | 10.55 | 4.08 | 10.08 | 11.29 | 1.72 |
| Interest coverage | — | — | — | -16.2 | -45.3 | — | — | -141.3 | -137.7 | — |
| Working capital | $58.4M | $58.2M | $94.1M | $87.5M | $139.2M | $124.8M | $68.8M | $103.1M | $79.1M | $5.0M |
| Invested capital | $21.7M | −$2.5M | $36.1M | −$26.5M | −$50.8M | $13.0M | −$1.9M | $635,000 | −$2.1M | −$146,000 |
| Tangible asset value | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M | $132.0M | $74.6M | $115.9M | $85.0M | $6.4M |
| Net current asset value | $57.4M | $42.9M | $55.7M | $60.2M | $75.1M | $117.7M | $63.9M | $102.3M | $78.8M | $4.5M |
| Graham number | $1.81 | — | $4.42 | — | — | — | — | — | — | — |
| Graham net-net per share | $0.84 | $0.51 | $0.73 | $1.56 | $2.12 | $4.65 | $2.84 | $6.18 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $54.5M | $47.5M | — | — | — | $0 | — |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 2,096.0% | 1.7% | 6.6% | 61.4% | 1.4% | 247.8% |
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 99.61 | 0.21 | 0.42 | 5.96 | 0.07 | 2.97 |
| Stock-based compensation / revenue | 7.3% | 16.2% | 7.6% | 18.8% | 307.2% | 52.4% | 79.6% | 69.3% | 72.1% | 53.7% |
| R&D / revenue | 64.5% | 201.7% | 49.6% | 98.0% | 2,101.8% | 718.1% | 1,387.1% | 854.4% | 1,660.9% | 7,860.6% |
| SG&A / revenue | 35.5% | 47.8% | 24.1% | 75.1% | 1,358.3% | 234.9% | 328.7% | 324.9% | 547.8% | 2,156.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 238.3 | 392.5 | 91.1 | 14.0 | 524.1 | 321.2 | 444.3 | 195.2 | 299.4 | 171.1 |
| Days of inventory on hand | — | — | -15.8 | -569.1 | -2,058.6 | -69.8 | -61.4 | -73.0 | -53.0 | — |
| Days payables outstanding | — | 16.4 | 7.1 | 202.7 | 368.6 | 14.4 | 21.5 | 38.1 | 25.6 | 20.3 |
| Cash conversion cycle (days) | — | 376.1 | 68.1 | -757.8 | -1,903.1 | 237.0 | 361.3 | 84.1 | 220.9 | 150.7 |
| Receivables turnover | 1.53 | 0.93 | 4.01 | 26.08 | 0.70 | 1.14 | 0.82 | 1.87 | 1.22 | 2.13 |
| Payables turnover | 0.00 | 22.28 | 51.57 | 1.80 | 0.99 | 25.27 | 16.97 | 9.58 | 14.26 | 17.96 |
| Asset turnover | 0.66 | 0.33 | 0.68 | 0.33 | 0.02 | 0.07 | 0.04 | 0.04 | 0.04 | 0.03 |
| Average receivables | $38.9M | $51.6M | $25.9M | $1.9M | $4.4M | $8.2M | $5.8M | $2.1M | $1.6M | $157,000 |
| Average payables | $4.0M | $4.3M | $997,500 | $859,000 | $1.1M | $2.7M | $3.9M | $3.5M | $2.3M | $1.5M |
| Average inventory | — | — | −$2.2M | −$2.4M | −$6.3M | −$12.8M | −$11.1M | −$6.8M | −$4.8M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SPRO's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SPRO valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Spero Therapeutics traded at 16.0 times earnings. Based on the latest twelve months, the trailing P/E is 7.9. Spero Therapeutics earned a return on equity of 16.3% and a return on invested capital of −0.2% in fiscal 2025. It ended the year with $2.9 million of debt and $40.3 million in cash and short-term investments, a net cash position of $37.4 million.
See the SPRO income statement, the SPRO chart for price history, or the SPRO stock overview for the latest quote and news.
SPRO key metrics FAQ
What is Spero Therapeutics's P/E ratio?
Spero Therapeutics's trailing P/E ratio is 7.9 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was 16.0.
What is Spero Therapeutics's EV/EBITDA?
Spero Therapeutics's enterprise value was 11.3 times EBITDA at the end of fiscal 2025 (enterprise value $100.2 million, EBITDA $8.8 million); the current EV/EBITDA is 3.8.
What is Spero Therapeutics's return on equity?
Spero Therapeutics's return on equity (ROE) was 16.3% in fiscal 2025: net income of $8.6 million on average shareholders' equity of $52.6 million.
What is Spero Therapeutics's ROIC?
Spero Therapeutics's return on invested capital was −0.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Spero Therapeutics have?
Spero Therapeutics had total debt of $2.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Spero Therapeutics's free cash flow yield?
Spero Therapeutics generated -$12.6 million of free cash flow in fiscal 2025, a free cash flow yield of −9.2% on its market value at year-end ($137.6 million).
What is Spero Therapeutics's current ratio?
Spero Therapeutics's current ratio was 7.59 at the end of fiscal 2025: current assets were 7.59 times current liabilities.